Fax: (011) 81-6-6789-3779
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer †
Article first published online: 12 SEP 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 4, pages 704–713, 15 February 2013
How to Cite
Iwata, H., Masuda, N., Sagara, Y., Kinoshita, T., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., Tsuda, H., Hayashi, N. and Noguchi, S. (2013), Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer . Cancer, 119: 704–713. doi: 10.1002/cncr.27818
Presented as an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2011; Chicago, IL.
- Issue published online: 4 FEB 2013
- Article first published online: 12 SEP 2012
- Manuscript Accepted: 13 AUG 2012
- Manuscript Revised: 9 AUG 2012
- Manuscript Received: 18 MAY 2012
- aromatase inhibitor;
- premenopausal breast cancer
The increasing costs associated with large-scale adjuvant trials mean that the prognostic value of biologic markers is increasingly important. The expression of nuclear antigen Ki-67, a marker of cell proliferation, has been correlated with treatment efficacy and is being investigated for its value as a predictive marker of therapeutic response. In the current study, the authors explored correlations between Ki-67 expression and tumor response, estrogen receptor (ER) status, progesterone receptor (PgR) status, and histopathologic response from the STAGE study (S_tudy of T_amoxifen or A_rimidex, combined with G_oserelin acetate to compare E_fficacy and safety).
In a phase 3, double-blind, randomized trial (National Clinical Trials identifier NCT00605267), premenopausal women with ER-positive, early stage breast cancer received either anastrozole plus goserelin or tamoxifen plus goserelin for 24 weeks before surgery. The Ki-67 index, hormone receptor (ER and PgR) status, and histopathologic responses were determined from histopathologic samples that were obtained from core-needle biopsies at baseline and at surgery. Tumor response was determined by using magnetic resonance imaging or computed tomography.
In total, 197 patients were randomized to receive either anastrozole plus goserelin (n = 98) or tamoxifen plus goserelin (n = 99). The best overall tumor response was better for the anastrozole group compared with the tamoxifen group both among patients who had a baseline Ki-67 index ≥20% and among those who had a baseline Ki-67 index <20%. There was no apparent correlation between baseline ER status and the Ki-67 index in either group. Positive PgR status was reduced from baseline to week 24 in the anastrozole group.
In premenopausal women with ER-positive breast cancer, anastrozole produced a greater best overall tumor response compared with tamoxifen regardless of the baseline Ki-67 index. Cancer 2013. © 2012 American Cancer Society.